New EMT antibody panel is released

New EMT antibody panel is released

Epithelial-mesenchymal transition (EMT) is a process by which polarized epithelial cells are transformed into mesenchymal cells and shows reduced cell adhesion, increased motility and invasive properties. EMT is a key driver of cancer metastasis. Targeting EMT in cancer cells has become an aim of pharmaceutical development.

arigo is proud to introduce the newly launched EMT antibody panel (ARG30320) which is ideal to facilitate EMT-related studies.

EMT antibody panel (ARG30320)

Component Clonality Reactivity Application Package
E-Cadherin antibody [SQab1717] Rabbit mAb Hu IHC-P, WB 20 ul
Vimentin antibody [SQab1721] Rabbit mAb Hu, Ms FACS, ICC/IF, IHC-P, IP, WB 20 ul
N-Cadherin antibody Rabbit pAb Hu, Ms, Rat, Sh ELISA, FACS, ICC/IF, IHC-P, IP, WB 20 ul
GAPDH antibody [SQab1878] Rabbit mAb Hu, Ms, Rat, Bo, Ch,
Mk, Pig, Xl, Zfsh
anti-Rabbit IgG antibody (HRP) Goat pAb Rb ELISA, IHC-P, WB 50 ul


* Includes both epithelial and mesenchymal markers
* Includes the most suitable loading control
* Includes secondary antibody
* Comprises antibodies with good performance

E-Cadherin antibody [SQab1717]

Vimentin antibody [SQab1721]

N-Cadherin antibody